Alex Herrera, MD, discusses the potential role of camidanlumab tesirine in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial.
Alex Herrera, MD, a hematologist/oncologist, and an assistant professor in the Department of Hematology and Hemtopoietic Cell Transplantation at City of Hope, discusses the potential role of camidanlumab tesirine (ADCT-301) in patients with relapsed/refractory Hodgkin Lymphoma, which is currently being examined in a phase 2 clinical trial (NCT04052997).
Patients with relapsed/refractory Hodgkin lymphoma who have developed resistance to brentuximab vedotin (Adcetris) and/or PD-1 blockade have limited treatment options, according to Herrera. The curative potential of these agents, especially when administered once a patient is relapsed/refractory or given a monotherapy, is fairly low, Herrera says. Due to this, there is an urgent need for novel agents utilizing new targets that can demonstrate efficacy in patients who have resistant disease.
Camidanlumab tesirine can potentially address the challenge faced in this patient population, Herrera says. The phase 2 trial enrolled patients who had previously been treated with brentuximab vedotin; therefore, camidanlumab tesirine can be applied to this patient population, Herrera says. The safety and efficacy data from the trial will help determine the role of the agent in patients with relapsed/refractory Hodgkin lymphoma, Herrera concludes.